News

The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy. Kresladi comprises the patient’s own haematopoietic stem cells that

The deal was originally announced in December 2025. With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) +

The European Commission (EC) has approved Novartis’ Rhapsido (remibrutinib) for certain CSU patients, becoming the first oral treatment for the skin disease. Rhapsido is approved for adult CSU

Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women’s health and general medicines, including biosimilars, reaching 140 countries.

The initiative aims to link external scientific data with internal R&D planning by creating a unified system that supports decision-making, improves market forecasting, and helps prioritise strategic investments.

Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. The partnership aims to establish a robust platform for speciality medicines

The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from

The collaboration aims to implement an agentic platform across MSD’s research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams

The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without suppressing immune